Prelude Therapeutics Inc stock is traded at $3.60, with a volume of 140,535. It is up +1.27% in the last 24 hours and down -5.51% over the past month. Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
Previous Close:
$3.56
Open:
$3.48
24h Volume:
140,535
Relative Volume:
0.56
Market Cap:
$287.29M
Revenue:
$16.72M
Net Income/Loss:
-$77.80M
P/E Ratio:
-
EPS:
-$1.06
Net Cash Flow:
-$43.78M
1W Performance:
-7.22%
1M Performance:
-5.51%
6M Performance:
-25.62%
1Y Performance:
+166.67%
1-Day Range:
$3.34$3.68
1-Week Range:
$3.34$4.17
52-Week Range:
$1.17$6.83
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(302) 467-1280Address
175 INNOVATION BOULEVARD, WILMINGTON, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS